Recombinant Human Livin protein is a Human Full Length protein, expressed in Escherichia coli, with >90% purity and suitable for SDS-PAGE.
M G S S H H H H H H S S G L V P R G S H M G P K D S A K C L H R G P Q P S H W A A G D G P T Q E R C G P R S L G S P V L G L D T C R A W D H V D G Q I L G Q L R P L T E E E E E E G A G A T L S R G P A F P G M G S E E L R L A S F Y D W P L T A E V P P E L L A A A G F F H T G H Q D K V R C F F C Y G G L Q S W K R G D D P W T E H A K W F P S C Q F L L R S K G R D F V H S V Q E T H S Q L L G S W D P W E E P E D A A P V A P S V P A S G Y P E L P T P R R E V Q S E S A Q E P G G V S P A E A Q R A W W V L E P P G A R D V E A Q L R R L Q E E R T C K V C L D R A V S I V F V P C G H L V C A E C A P G L Q L C P I C R A P V R S R V R T F L S
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control (PubMed:11024045, PubMed:11084335, PubMed:11162435, PubMed:16729033, PubMed:17294084). Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity (PubMed:11024045, PubMed:16729033). As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival (PubMed:16729033). May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions (PubMed:16729033). Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine (PubMed:11084335, PubMed:11162435, PubMed:11865055). Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2 (PubMed:11865055). This activation depends on TAB1 and MAP3K7/TAK1 (PubMed:11865055). In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9 (PubMed:11024045). Isoform 1. Blocks staurosporine-induced apoptosis (PubMed:11322947). Promotes natural killer (NK) cell-mediated killing (PubMed:18034418). Isoform 2. Blocks etoposide-induced apoptosis (PubMed:11162435, PubMed:11322947). Protects against natural killer (NK) cell-mediated killing (PubMed:18034418).
KIAP, LIVIN, MLIAP, RNF50, UNQ5800/PRO19607/PRO21344, BIRC7, Baculoviral IAP repeat-containing protein 7, Kidney inhibitor of apoptosis protein, Livin, Melanoma inhibitor of apoptosis protein, RING finger protein 50, RING-type E3 ubiquitin transferase BIRC7, ML-IAP
Recombinant Human Livin protein is a Human Full Length protein, expressed in Escherichia coli, with >90% purity and suitable for SDS-PAGE.
pH: 8
Constituents: 20% Glycerol (glycerin, glycerine), 0.58% Sodium chloride, 0.242% Tris, 0.0584% EDTA, 0.0154% (R*,R*)-1,4-Dimercaptobutan-2,3-diol
ab87179 is purified using conventional chromatography techniques.
Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control (PubMed:11024045, PubMed:11084335, PubMed:11162435, PubMed:16729033, PubMed:17294084). Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity (PubMed:11024045, PubMed:16729033). As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival (PubMed:16729033). May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions (PubMed:16729033). Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine (PubMed:11084335, PubMed:11162435, PubMed:11865055). Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2 (PubMed:11865055). This activation depends on TAB1 and MAP3K7/TAK1 (PubMed:11865055). In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9 (PubMed:11024045).
Belongs to the IAP family.
Autoubiquitinated and undergoes proteasome-mediated degradation.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3ug by SDS-PAGE under reducing conditions and visualized by coomassie blue stain.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com